ALLMedicine Torsade De Pointes Center

Jun 2nd, 2020 - QT interval prolongation is a growing concern worldwide, posing psychiatric patients to life-threatening fatal arrhythmias i.e., torsade de pointes. This study aimed to identify the prevalence of QT interval prolongation, its associated risk facto...

May 28th, 2020 - Antiarrhythmic drugs therapies are currently going through a turning point. The high risk that exists during the treatments has led to an ongoing search for new non-invasive toxicity risk biomarkers. We propose the use of spatial biomarkers obtain...

May 24th, 2020 - QTc interval prolongation can lead to life-threatening complications such as torsade de pointes (TdP), ventricular tachycardia (VT), and sudden cardiac death (SCD). It can occur with tyrosine kinase inhibitors (TKIs) but comparative real-world ana...

May 14th, 2020 - There is no known effective therapy for patients with COVID-19. Initial reports suggesting the potential benefit of Hydroxychloroquine/Azithromycin (HY/AZ) have resulted in massive adoption of this combination worldwide. However, while the true ef...

May 5th, 2020 - Prolongation of the QT interval by antiarrhythmic drugs is the primary cause of torsade de pointes. Although there are previous reports of drug-induced torsade de pointes in patients undergoing hemodialysis, torsade de pointes caused by a sudden d...

Feb 9th, 2010 - Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.|2010|Drew BJ,Ackerman MJ,Funk M,Gibler WB,Kligfield P,|physiology,epidemiology,phy...

Jun 2nd, 2020 - QT interval prolongation is a growing concern worldwide, posing psychiatric patients to life-threatening fatal arrhythmias i.e., torsade de pointes. This study aimed to identify the prevalence of QT interval prolongation, its associated risk facto...

May 28th, 2020 - Antiarrhythmic drugs therapies are currently going through a turning point. The high risk that exists during the treatments has led to an ongoing search for new non-invasive toxicity risk biomarkers. We propose the use of spatial biomarkers obtain...

May 24th, 2020 - QTc interval prolongation can lead to life-threatening complications such as torsade de pointes (TdP), ventricular tachycardia (VT), and sudden cardiac death (SCD). It can occur with tyrosine kinase inhibitors (TKIs) but comparative real-world ana...

May 14th, 2020 - There is no known effective therapy for patients with COVID-19. Initial reports suggesting the potential benefit of Hydroxychloroquine/Azithromycin (HY/AZ) have resulted in massive adoption of this combination worldwide. However, while the true ef...

May 5th, 2020 - Prolongation of the QT interval by antiarrhythmic drugs is the primary cause of torsade de pointes. Although there are previous reports of drug-induced torsade de pointes in patients undergoing hemodialysis, torsade de pointes caused by a sudden d...

Apr 8th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The nation's leading cardiology associations urged caution with hydroxychloroquine and azithromycin for COVID-19 in patients with cardiovascular d...

Aug 6th, 2019 - Certain Ellipse implantable cardioverter defibrillators from Abbott are under Class I recall because of electrical failures attributed to a faulty manufacturing process, the FDA announced. Thanks to artificial intelligence, the VMS+ system may all...

Aug 8th, 2018 - NEW YORK (Reuters Health) - Certain oral contraceptives may increase the risk of drug-induced Torsade de Pointes in women with preexisting risk factors, a new study suggests. In healthy young women who'd been treated with sotalol, which prolongs t...

Aug 1st, 2018 - Action Points Healthy women on oral contraceptives may have a higher risk for drug-induced alterations of ventricular repolarization. Note that the results generate the hypothesis that drospirenone may be a risk factor for drug-induced torsade de ...

Jun 18th, 2013 - Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg Zivin K, Pfeiffer PN, Bohnert AS, et al Am J Psychiatry. 2013;170:642-650 Study Summary Clinicians (including myself) have struggled to deal with a US Food and D...